Stephen R. Plymate, M.D.
Research Interest: Dr. Plymate’s laboratory focuses on prostate cancer and its treatment. There are three areas of funded research in his program. Specific areas of investigation include: 1): control of prostate cancer growth and metastasis by inhibition of the type 1 IGF receptor with human monoclonal antibodies. Results in this area over the past year have shown that IGF-IR inhibition markedly enhances effects of castration by altering nuclear localization of the androgen receptor by changing AR phosphorylation sites. This work is funded by NIH/NCI. 2): The role of androgen receptor splice variants in castration resistant prostate cancer. This work is funded by NCI/NIH, NCI SPORE, DOD-CDMRP Transformative Grant Award, and a VA-Merit review. 3): The role of Bumped Kinase Inhibitors on inhibition of PKD3 in castration resistant prostate cancer.
Education and Training:
College: 1964, University of Nebraska College of Medicine
Medical School: 1968, University of Nebraska College of Medicine
Residency: 1968-1971, Madigan Army Medical Center, Tacoma, WA
Fellowship: 1971-1973, Endocrinology, University of Washington, USPHSH
Publications: Go to PubMed.
Clinic Information: Dr. Plymate attends in the Prostate Cancer Clinic at VAPSHCS, the TCU at VAPSHCS, and with the Geriatrics consult service and Medicine Wards at Harborview Medical Center.
General Information: Email Dr. Plymate.